2023
MGMT promoter methylation in 1p19q-intact gliomas
Kinslow C, Siegelin M, Iwamoto F, Gallitto M, Neugut A, Yu J, Cheng S, Wang T. MGMT promoter methylation in 1p19q-intact gliomas. Journal Of Neuro-Oncology 2023, 166: 73-78. PMID: 38114801, DOI: 10.1007/s11060-023-04515-z.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMGMT promoter methylationOverall survivalIDH-wildtypeMGMT statusAdjuvant temozolomideAnaplastic gliomasPromoter methylationAssociated with poor survivalAssociation of MGMTClinical efficacy of temozolomideIDH-mutant astrocytomasCox proportional hazards regression modelsIDH-wildtype gliomasKaplan-Meier methodWell-powered prospective studiesMGMT promoter statusEfficacy of temozolomideProportional hazards regression modelsInternational randomized phaseStandard-of-careHazards regression modelsCATNON trialAnaplastic astrocytomaCancer DatabaseMGMT Promoter Methylation Predicts Survival in 1p19q-Codeleted Gliomas after Chemotherapy
Kinslow C, Rae A, Kumar P, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Yu J, Kachnic L, Cheng S, Wang T. MGMT Promoter Methylation Predicts Survival in 1p19q-Codeleted Gliomas after Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e117. DOI: 10.1016/j.ijrobp.2023.06.902.Peer-Reviewed Original ResearchMGMT promoter methylationMGMT promoter statusMGMT promoter methylation statusAssociated with poor survivalNational Cancer DatabaseOverall survivalUnmethylated MGMTPromoter methylation statusPromoter methylationPromoter statusAlkylating chemotherapyPoor survivalMultivariate Cox proportional hazards regression modelsResponse to alkylating chemotherapyProgression-free survivalCox proportional hazards regression modelsMethylation statusProportional hazards regression modelsReceipt of chemotherapyHazards regression modelsCourse of treatmentAnaplastic gliomasMGMT promoterCancer DatabaseDiagnosed gliomas
2005
Phosphorylated FADD induces NF-κB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas
Chen G, Bhojani M, Heaford A, Chang D, Laxman B, Thomas D, Griffin L, Yu J, Coppola J, Giordano T, Lin L, Adams D, Orringer M, Ross B, Beer D, Rehemtulla A. Phosphorylated FADD induces NF-κB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, 102: 12507-12512. PMID: 16109772, PMCID: PMC1194899, DOI: 10.1073/pnas.0500397102.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinomaApoptosisCell CycleCell NucleusCell ProliferationDNA, NeoplasmElectrophoresis, Gel, Two-DimensionalFas-Associated Death Domain ProteinGene AmplificationGene ExpressionHumansJurkat CellsLung NeoplasmsMutationNF-kappa BOligonucleotide Array Sequence AnalysisPhosphorylationPrognosisRNA, MessengerRNA, NeoplasmRNA, Small InterferingSerineConceptsFas-associated death domainCell cycle progressionP-FADDCell cyclePhosphorylated Fas associated death domainAnalysis of copy numberRegulation of cell cycle progressionNF-kappaB activationNF-kappaBPerturbed cell cycleElevated NF-kappaBCDNA microarray analysisInduction of NF-kappaB activityFADD geneDeath domainNonphosphorylatable formPoor outcomeLung cancerCDNA microarrayLung adenocarcinomaNuclear localizationCycle progressionCopy numberTissue microarray analysisAssociated with poor survival